SL
NKTR icon

Salomon & Ludwin’s Nektar Therapeutics NKTR Stock Holding History

Salomon & Ludwin’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$182 – 2195
2025
Q3 		$182 Hold
3
– – ﹤0.01% 2122
2025
Q2 		$77 Hold
3
– – ﹤0.01% 1099
2025
Q1 		$31 Hold
3
– – ﹤0.01% 710
2024
Q4 		$43 Hold
3
– – ﹤0.01% 712
2024
Q3 		$60 Hold
3
– – ﹤0.01% 726
2024
Q2 		$57 Hold
3
– – ﹤0.01% 725
2024
Q1 		$43 Hold
3
– – ﹤0.01% 841
2023
Q4 		$27 Hold
3
– – ﹤0.01% 754
2023
Q3 		$27 Buy
+3
New +$29 ﹤0.01% 751

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Salomon & Ludwin's NKTR Position: Q4 2025 in Review

Salomon & Ludwin sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 3 shares — an estimated $182 sold.

Salomon & Ludwin first reported a position in NKTR in Q3 2023 and held it in 9 quarters. The position peaked at $182 in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • Salomon & Ludwin reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Salomon & Ludwin sold 3 Nektar Therapeutics shares in Q4 2025, an estimated $182.
  • Salomon & Ludwin first reported a position in Nektar Therapeutics in Q3 2023 and held it in 9 quarters.
  • Salomon & Ludwin's Nektar Therapeutics position peaked at $182 in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Salomon & Ludwin's 13F filing for Q4 2025, filed 28 Jan 2026.